Discovery and evaluation of Cav3.1-selective T-type calcium channel blockers was written by Bezencon, Olivier;Remen, Lubos;Richard, Sylvia;Roch, Catherine;Kessler, Melanie;Moon, Richard;Mawet, Jacques;Ertel, Eric A.;Pfeifer, Thomas;Capeleto, Bruno. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2017.Application In Synthesis of Ethyl 1,5-diphenyl-1H-pyrazole-3-carboxylate The following contents are mentioned in the article:
The authors identified and characterized a series of pyrazole amides as potent, selective Cav3.1-blockers. This series culminated with the identification of pyrazole amides (I) and (II), with excellent potencies and/or selectivities toward the Cav3.2- and Cav3.3-channels. This compound displays poor DMPK properties, making its use difficult for in vivo applications. Nevertheless, this compound as well as analogous ones are well-suited for in vitro studies. This study involved multiple reactions and reactants, such as Ethyl 1,5-diphenyl-1H-pyrazole-3-carboxylate (cas: 17355-75-8Application In Synthesis of Ethyl 1,5-diphenyl-1H-pyrazole-3-carboxylate).
Ethyl 1,5-diphenyl-1H-pyrazole-3-carboxylate (cas: 17355-75-8) belongs to pyrazole derivatives. As is the case with imidazoles, the pyrazole ring offers many opportunities to create new multiring systems that incorporate this heterocycle. Pyrazole the presence of this nucleus in pharmacological agents of diverse therapeutic categories such as celecoxib, a potent anti-inflammatory, the antidepressant agent fezolamide have proved the pharmacological potential of the pyrazole moiety. Application In Synthesis of Ethyl 1,5-diphenyl-1H-pyrazole-3-carboxylate
Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics